Intra-substance steroid injection for full-thickness supraspinatus tendon rupture

Table 1 Average values and standard deviations in group 1 and group 2

	Age	RS BI	RS 3 M	RS 6 M	Pain BI	Pain 1 W	Pain 3 M	Pain 6 M	Dis BI	Dis 1 W	Dis 3 M	Dis 6 M	Total BI	Total 1 W	Total 3 M	Total 6 M	VAS BI	VAS 1 W	VAS 3 M	VAS 6 M
Ave in group1	66.25	1.89	1.96	2.01	61.5	34	38.67	45.5	43.5	26.83	28.58	31.67	50.33	29.42	32.42	37	8.08	4	5	5.92
SD in group1	4.42	0.63	0.62	0.56	7.02	7.57	9.96	11.45	9.90	6.30	7.34	9.33	8.39	6.66	8.18	10.05	0.83	0.88	1.04	1.38
Ave in group2	66.33	2.03	2.08	2.15	59.33	49.33	55.5	56.17	42.58	39	40.92	41	49	42.67	46.25	46.75	7.67	6.17	7.17	7.33
SD in group2	4.01	0.52	0.36	0.40	5.45	4.53	5.66	5.84	5.81	5.19	4.48	5.20	5.23	4.56	4.44	4.74	0.72	0.66	0.86	0.91

Ave average, SD standard deviation, RS rupture size, Pain SPADI pain score, Dis SPADI disability score, Total SPADI total score, VAS pain VAS score, BI before injection, 1 W 1 week after injection, 3 M 3 months after injection, 6 M 6 months after injection
The size of the supraspinatus tendon rupture did not increase in both groups. In both groups, pain and function significantly improved after the injection. The pain and function scores both improved more in Group 1 than in Group 2

ISSN: 1471-2474